NCT04526132已完成3 期
A Multi-center, Randomized, Double-blind, Placebo Parallel Controlled Phase Ⅲ Clinical Trial on the Efficacy and Safety of Felbinac Trometamol Injection in the Treatment of Moderate and Severe Postoperative Pain
Shijiazhuang Yiling Pharmaceutical Co. Ltd1 个研究点 分布在 1 个国家目标入组 306 人开始时间: 2021年4月25日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 306
- 试验地点
- 1
- 主要终点
- 24h total morphine consumption
研究概览
简要总结
A multi-center, randomized, double-blind, placebo parallel controlled phase Ⅲ clinical trial on the efficacy and safety of felbinac trometamol Injection in the treatment of moderate and severe postoperative pain.main purpose is to evaluate the efficacy of Felbinac Trometamol Injection in the treatment of moderate and severe pain after surgery.Secondary purpose is to evaluation the safety of Felbinac Trometamol Injection in the treatment of moderate and severe pain after surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18≤age≤65 years of age, gender is not limited;
- •ASA grade I or II;
- •18 ≤ body mass index (BMI) ≤ 30 [BMI = weight (kg) / height 2 (m2)];
- •Expected hospital stay ≥72 hours after surgery；
- •Patients planned to receive laparotomy or laparoscopic upper abdominal surgery with a single surgical incision ≥5 cm, thoracoscopic chest surgery (such as lung lobe resection surgery, lung wedge resection surgery, etc.),both under general anesthesia;
- •Expected to require more than 48 hours of PCIA (patient controlled intravenous analgesia) treatment after surgery;
- •Ability to understand research procedures and pain scales, operate PCIA devices, and communicate effectively with researchers;
- •Agree to participate in the trial and voluntarily sign the informed consent form.
排除标准
- •Except for the chronic pain caused by the target lesion of this operation, those who have a history of chronic pain for more than 3 months or who are undergoing regular analgesia for more than 3 months;
- •Those who have used barbiturates within 20 days before surgery, those who used other analgesics, muscle relaxants or sedatives within 24 hours before operation (excluding those required for this operation), or those who used long-acting non-steroidal anti-inflammatory drugs (NSAIDs) within 12 hours, or those who used short-acting non-steroidal anti-inflammatory drugs (NSAIDs) within 6 hours before operation.
- •A person with high bleeding risk, and also including who with congenital bleeding disorders (such as hemophilia), thrombocytopenia (PLT < 80 × 10 ∧ 9 / L), abnormal platelet function (such as idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, congenital platelet dysfunction, etc.) or any clinically significant active bleeding, coagulopathy;
- •A person who received full-dose anticoagulant therapy, activated protein C or thrombolytic drugs within 6 hours before surgery (except for heparin subcutaneous injection for preventive treatment);
- •People with heart failure (NYHA grade III or IV), unstable angina pectoris, acute myocardial infarction, and severe arrhythmia within 6 months before surgery
- •Hypertensive patients who have not been satisfactorily controlled by blood pressure (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥105mmHg), or ACEI/diuretics for ≥30 days, or hypotension (systolic blood pressure <90mmHg);
- •People with pulmonary heart disease or other serious respiratory diseases that are not the purpose of this treatment;
- •Person with gastrointestinal ulcer and a history of gastrointestinal bleeding 6 months before operation and required medical treatment(prophylactic medication or undiagnosed persons are not excluded);
- •Those with previous cerebral arteriovenous malformations, cerebral aneurysms, brain tumors, or preoperative traumatic brain injury, intracranial surgery, history of stroke;
- •Patients with poor glycemic control of diabetes (random blood glucose > 11.1mmol / L);
- •Patients with autoimmune diseases, connective tissue diseases, etc. who need long-term use of adrenocortical hormone therapy;
- •Abnormal liver and kidney function: ALT/AST> 2 times the upper limit of normal value, or creatinine> upper limit of normal value, or dialysis treatment within 28 days before surgery;
- •Allergic constitution, or known to be allergic to this drug, NSAIDs, and opioids;
- •Patients who are afflicted with narcotic drugs, drugs, or resistant to opioids;
- •A woman who is breast-feeding or pregnant, who is unable or unwilling to follow the investigator's guidance during the study period and within 3 months after the last study treatment;
- •Those who have participated in other clinical trials within 3 months before surgery;
- •Investigators believe that it is not suitable for participating in this research.
研究组 & 干预措施
Experimental: group1
Experimental
Generic name: Felbinac Trometamol Injection; Placebo:Normal saline Dosage form: Injection Dosage:8ml Volume:4ml
干预措施: Felbinac Trometamol Injection (Drug)
Experimental: group2
Placebo Comparator
Generic name:Placebo Placebo:Normal saline Dosage form:Injection Dosage:8mg Volume:4ml
干预措施: Placebos (Drug)
结局指标
主要结局
24h total morphine consumption
时间窗: up to 24hours after multi-dose
The total amount of morphine within 24 hours after the end of first drug administration
次要结局
- Area under the pain intensity curve during movement (AUCM)(0-8 h，8-16 h，16-24 h and 0-48 h)
- Total and effective pressing times of analgesic pump(up to 24 and 48 hours after multi-dose)
- The proportion of morphine used to remedy analgesia(up to 24 and 48 hours after multi-dose)
- Pain intensity at 48 hours after the end of the first administration under movement(up to 48 hours after multi-dose)
- Pain intensity at 48 hours after the end of the first administration under rest(up to 48 hours after multi-dose)
- Total amount of morphine administered within 48 hours after the first administration(up to 48 hours after multi-dose)
- Press time(up to 48 hours after multi-dose)
- Area under the pain intensity curve during rest(AUCR)(0-8 h，8-16 h，16-24 h and 0-48 h)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Phase # Clinical Study Trial of Felbinac Trometamol Injection in ChinaPainNCT05297669Shijiazhuang Yiling Pharmaceutical Co. Ltd264
Unknown
3 期
Clinical Trial to Evaluate the Efficacy and Safety of 'Pelubiprofen Controlled Released Tab.' in Acute Traumatic InjuryAcute Traumatic InjuryNCT03874247Daewon Pharmaceutical Co., Ltd.94
已完成
3 期
Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart FailureChronic Systolic Heart FailureNCT04468529Zensun Sci. & Tech. Co., Ltd.154
已完成
3 期
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT05814393JW Pharmaceutical200
已完成
3 期
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DMType 2 Diabetes MellitusNCT05814406JW Pharmaceutical196